Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients
| العنوان: | Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients |
|---|---|
| المؤلفون: | Peter C.M. van de Kerkhof, Marieke M B Seyger, Finola M. Bruins, Inge M G J Bronckers, Elke M G J de Jong, Hans Groenewoud |
| المصدر: | Jama Dermatology, 156, 1, pp. 72-78 Jama Dermatology, 156, 72-78 |
| بيانات النشر: | American Medical Association (AMA), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Adolescent, Administration, Topical, Stress-related disorders Donders Center for Medical Neuroscience [Radboudumc 13], Administration, Oral, Dermatology, Severity of Illness Index, Injections, 030207 dermatology & venereal diseases, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Quality of life, Interquartile range, Psoriasis Area and Severity Index, Psoriasis, Internal medicine, medicine, Humans, Prospective Studies, Child, Netherlands, Body surface area, Biological Products, business.industry, Other Research Radboud Institute for Health Sciences [Radboudumc 0], Dermatology Life Quality Index, medicine.disease, humanities, Treatment Outcome, Child, Preschool, 030220 oncology & carcinogenesis, Cohort, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], Quality of Life, Female, Ultraviolet Therapy, Dermatologic Agents, business, Follow-Up Studies, Cohort study |
| الوصف: | Treatment of psoriasis is associated with improved quality of life (QOL) in those with the disease. However, in daily clinical practice, the association between the degree of psoriasis clearance and QOL has not been studied to date, especially in the pediatric population.To identify the association between the degree of psoriasis improvement (as measured by the Psoriasis Area Severity Index [PASI] and body surface area [BSA] response) and QOL (as measured by the Children's Dermatology Life Quality Index [CDLQI]) in pediatric psoriasis, and to assess the association of treatment type with QOL, independent of psoriasis improvement.Data used in this single-center cohort study were extracted from the Child-CAPTURE (Continuous Assessment of Psoriasis Treatment Use Registry), a prospective, observational, daily clinical practice cohort of all children (aged18 years) with a psoriasis diagnosis who attended the outpatient clinic of the Department of Dermatology at the Radboud University Medical Center in Nijmegen, the Netherlands, between September 3, 2008, and May 4, 2018. All records of treatment episodes with CDLQI, PASI, and BSA scores were included in the analysis.Patients were treated according to daily clinical care. Treatments were clustered into topical, dithranol, conventional systemic, and biological treatments. Because of low numbers of UV-B phototherapy, this treatment was not assessed.Primary outcomes were mean change of CDLQI scores per PASI and BSA response categories (0 to50, 50 to75, 75 to90, and ≥90) and mean CDLQI change per treatment categories.In total, 319 patients (median [interquartile range] age, 10.0 [7.0] years; 183 female [57.4%]) were analyzed for PASI score improvement (399 treatment episodes) and improvement in BSA involvement (366 treatment episodes). The greatest improvements in CDLQI scores were seen in the PASI ≥90 response category, with an estimated marginal mean change in CDLQI score of -6.6 (95% CI, -7.5 to -5.7). The greatest improvements in CDLQI scores were also observed in the BSA ≥90 response category, with an estimated marginal mean change in CDLQI score of -6.8 (95% CI, -7.5 to -6.1). Systemic treatment demonstrated a greater degree of improvement of CDLQI compared with topical treatment, independent of PASI response categories.This cohort study in a real-world setting found that the greatest improvements in QOL were associated with PASI 90 or greater, a decrease in BSA involvement of 90% or greater, and systemic treatments. These findings suggest that reaching PASI 90 or greater and decreasing BSA involvement by at least 90% may be clinically meaningful treatment goals that will help pediatric patients with psoriasis reach optimal QOL. |
| وصف الملف: | application/pdf |
| تدمد: | 2168-6068 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05540cc6be6a11a8e5e51cc2954b93d3Test https://doi.org/10.1001/jamadermatol.2019.3717Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....05540cc6be6a11a8e5e51cc2954b93d3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 21686068 |
|---|